NCT05039268View on ClinicalTrials.gov

3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS)

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 25, 2021

Primary Completion Date

September 12, 2022

Study Completion Date

September 12, 2022

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

3K3A-APC Protein

3K3A-APC with intravenous dosing of five doses of either 15mg or 30mg at 12 hourly interval. The first 8 patients will receive 15mg dose, and the next 8 patients will receive 30mg dose.

Trial Locations (1)

2113

Macquarie University, Macquarie Park

All Listed Sponsors
collaborator

ZZ Biotech, LLC

INDUSTRY

lead

Macquarie University, Australia

OTHER

NCT05039268 - 3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS) | Biotech Hunter | Biotech Hunter